Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

Ou Yamaguchi(Saitama International Medical Center), Hiroshi Kagamu(Saitama International Medical Center)

Thoracic Cancer

March 19, 2019

10.1111/1759-7714.13044

Cited by 51

Related Papers

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

|The Lancet Oncology|2019|636